{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T18:20:29Z","timestamp":1788286829948,"version":"build-2803163510"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.ejca.2023.113311","type":"journal-article","created":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T11:55:50Z","timestamp":1692964550000},"page":"113311","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Phase II study of trifluridine\/tipiracil in metastatic breast cancers with or without prior exposure to fluoropyrimidines"],"prefix":"10.1016","volume":"193","author":[{"given":"Joline S.J.","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel G.W.","family":"Ow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea L.A.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matilda X.W.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria H.J.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia Li","family":"Low","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghav","family":"Sundar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan R.E.","family":"Choo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan Qin","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne L.E.","family":"Ang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bee Choo","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo Chin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2023.113311_bib1","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pky062","article-title":"Change in survival in metastatic breast cancer with treatment advances: meta-analysis and systematic review","volume":"2","author":"Caswell-Jin","year":"2018","journal-title":"JNCI Cancer Spectr"},{"key":"10.1016\/j.ejca.2023.113311_bib2","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2023.113311_bib3","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1200\/JCO.1998.16.10.3439","article-title":"Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women","volume":"16","author":"Fossati","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.113311_bib4","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1053\/ctrv.1999.0161","article-title":"Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer","volume":"26","author":"Stockler","year":"2000","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejca.2023.113311_bib5","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S1470-2045(02)00927-0","article-title":"Chemotherapy for metastatic breast cancer-report of a European expert panel","volume":"3","author":"Crown","year":"2002","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2023.113311_bib6","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3892\/etm.2011.244","article-title":"Trifluorothymidine exhibits potent antitumor activity via the induction of DNA double-strand breaks","volume":"2","author":"Suzuki","year":"2011","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.ejca.2023.113311_bib7","first-page":"571","article-title":"A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA","volume":"25","author":"Emura","year":"2004","journal-title":"Int J Oncol"},{"key":"10.1016\/j.ejca.2023.113311_bib8","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","article-title":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer","volume":"372","author":"Mayer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2023.113311_bib9","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/S1470-2045(18)30739-3","article-title":"Trifluridine\/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"19","author":"Shitara","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2023.113311_bib10","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2006.24.18_suppl.10576","article-title":"Phase I study to determine the safety of oral administration of TAS-102 on a twice daily (BID) schedule for five days a week (wk) followed by two days rest for two wks, every (Q) four wks in patients (pts) with metastatic breast cancer (MBC)","volume":"24","author":"Green","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.113311_bib11","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2023.113311_bib12","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","article-title":"CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment","volume":"13","author":"Trotti","year":"2003","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.ejca.2023.113311_bib13","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.1999.17.2.485","article-title":"Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer","volume":"17","author":"Blum","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.113311_bib14","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1200\/JCO.2005.05.098","article-title":"Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer","volume":"23","author":"Miller","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.113311_bib15","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1634\/theoncologist.11-4-325","article-title":"Capecitabine monotherapy: safe and effective treatment for metastatic breast cancer","volume":"11","author":"Ershler","year":"2006","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2023.113311_bib16","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.ejca.2003.11.007","article-title":"Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer","volume":"40","author":"Fumoleau","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2023.113311_bib17","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1093\/annonc\/mdg346","article-title":"Multicenter phase II study of oral capecitabine (Xeloda(\")) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy","volume":"14","author":"Reichardt","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2023.113311_bib18","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2004.22.90140.815","article-title":"Capecitabine: single institution experience from North India in metastatic breast cancer","volume":"22","author":"Vaid","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.113311_bib19","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.3584","article-title":"Real-world experience on the efficacy and tolerability of biweekly trifluridine\/tipiracil with or without bevacizumab in metastatic colorectal cancer","volume":"40","author":"Ang","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.113311_bib20","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.2217\/pgs-2016-0133","article-title":"Capecitabine pharmacogenetics: historical milestones and progress toward clinical implementation","volume":"17","author":"Syn","year":"2016","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.ejca.2023.113311_bib21","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1200\/JCO.2007.15.2090","article-title":"Potential regional differences for the tolerability profiles of fluoropyrimidines","volume":"26","author":"Haller","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.113311_bib22","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","article-title":"Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study","volume":"377","author":"Cortes","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2023.113311_bib23","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1200\/JCO.2013.52.4892","article-title":"Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane","volume":"33","author":"Kaufman","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.113311_bib24","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N Engl J Med"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923004136?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923004136?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:41:58Z","timestamp":1760733718000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804923004136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":24,"alternative-id":["S0959804923004136"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2023.113311","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase II study of trifluridine\/tipiracil in metastatic breast cancers with or without prior exposure to fluoropyrimidines","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2023.113311","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113311"}}